This trial has been completed.

Condition plaque psoriasis
Treatments chs-1420, adalimumab
Phase phase 3
Target TNF-alpha
Sponsor Coherus Biosciences, Inc.
Start date August 2015
End date May 2016
Trial size 545 participants
Trial identifier NCT02489227, CHS-1420-02


This is a 3-part study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Primary purpose treatment
Masking participant, care provider, investigator, outcomes assessor
(Active Comparator)
Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be reassigned (1:1) to CHS-1420 or continue adalimumab treatment, 1 dose every 2 weeks for weeks 17-23. At week 24 subjects will switch to CHS-1420 open label until study end.
adalimumab Humira
CHS-1420 40mg 2 doses at Week 0/Day 0 then 1 dose every 2 weeks starting at Week 1 for 23 weeks. At Week 24 subjects will continue on to CHS-1420 open label until study end.

Primary Outcomes

Difference between the percentage of subjects in each treatment group achieving a 75% improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12
time frame: 12 weeks

Eligibility Criteria

All participants at least 18 years old.

Inclusion Criteria: - Male or female adults - PsO diagnosis for 6 months - Active disease: PASI greater than or equal to 12, Physician's Static Global Assessment (PSGA) score greater than or equal to 3 (based on a scale of 0-5), - Body Surface Area (BSA) involved with PsO greater than or equal to 10% Exclusion Criteria: - Forms of psoriasis other than PsO - Drug induced psoriasis - Positive QuantiFERON-tuberculosis (TB) Gold Test - Presence of significant comorbid conditions - Chemistry and hematology values outside protocol specified range - Major systemic infections

Additional Information

Official title A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
Description This is a 55-week, randomized, double-blind, active-control, parallel group, multicenter, global study in subjects with active, moderate to severe, chronic PsO. The study will consist of 24 weeks of administration of blinded study drug, divided into Treatment Period 1 and Treatment Period 2, then 23 weeks of administration of open-label CHS-1420 and a Follow-up visit 8 weeks after the last dose. Subjects who meet inclusion/exclusion criteria will be stratified by body mass index (BMI), and age and randomized 1:1 to receive CHS-1420 or Humira in Treatment Period 1. Subjects assigned to CHS-1420 will continue to receive CHS-1420 in Period 2. Subjects assigned to Humira in Period 1 will be randomly assigned (1:1) to either continue with Humira in Treatment Period 2 or to switch to CHS-1420 in Treatment Period 2. All subjects will receive open label CHS-1420 in Treatment Period 3.
Trial information was received from ClinicalTrials.gov and was last updated in March 2017.
Information provided to ClinicalTrials.gov by Coherus Biosciences, Inc..